Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voriconazole Therapeutic Drug Monitoring in Pediatric HSCT Patients
NCT02227797Phase 1Completed
- Sponsor
- Masonic Cancer Center
- Start
- Jan 2015
- Primary completion
- Sep 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of voriconazole in fungal infection, sponsored by Masonic Cancer Center. Primary endpoint: Maximum tolerated, minimum efficacious dose at 1 week. Started Jan 2015; status: completed.
02
Drugs
voriconazole
03
Conditions
fungal infection
Beyond the preview
Go deeper on NCT02227797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02227797.